Similarly, the percentage of CD3 + CD4 + CD48 + cells was significantly lower in B-ALL patients than in controls (92.7 ± 9.7% vs. 96.7 ± 10.3%, p < 0.0001). The gene discussed is CD48; the disease is precursor B-cell acute lymphoblastic leukemia.